{"id":"W2995532498","doi":"10.1093/neuonc/noz232","title":"A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Hospital; London Health Sciences Centre","funders":"National Cancer Institute; Deciphera Pharmaceuticals; Five Prime Therapeutics; American Society of Clinical Oncology; Sanofi; Celldex Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Bevacizumab; Medicine; Concomitant; Clinical endpoint; Combination therapy; Internal medicine; Phases of clinical research; Hazard ratio; Adverse effect; Oncology; Randomized controlled trial; Progression-free survival; Surgery; Overall survival; Clinical trial; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000431717,0.0004974134,0.003998451,0.0004890619,0.000051979,0.00001529188,0.0001685981,0.0001574678,0.0002022303],"category_scores_gemma":[0.0001265843,0.0002712962,0.0002458396,0.0004597474,0.0001424404,0.00008392552,0.00005203852,0.0003298402,0.00002129337],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003334322,"about_ca_system_score_gemma":0.0002946401,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008503337,"about_ca_topic_score_gemma":0.0004178711,"domain_scores_codex":[0.9962222,0.0008476027,0.001125991,0.0006914327,0.0006376471,0.0004751454],"domain_scores_gemma":[0.9968959,0.001143624,0.0007695602,0.0006486584,0.0003409277,0.000201322],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8957323,0.03991357,0.05586313,0.00003343689,0.001183717,0.0003473873,0.001545178,0.00004433031,0.000777145,0.00005025697,0.00007864328,0.004430878],"study_design_scores_gemma":[0.8073834,0.1833061,0.006299555,0.0001060161,0.0008703977,0.0000200995,0.0003021301,0.0003289181,0.000780607,0.000008405428,0.0003908788,0.0002034858],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822642,0.0001026743,0.000004042304,0.000627109,0.0002919252,0.01622521,0.00001363896,0.00005501144,0.0004161767],"genre_scores_gemma":[0.9977517,0.00004091371,0.0000608322,0.0003527159,0.00003002896,0.001649985,0.00003088067,0.00006306884,0.00001990739],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1433925,"threshold_uncertainty_score":0.9999739,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008743713209318665,"score_gpt":0.280442104597949,"score_spread":0.2716983913886303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}